Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
United Airlines Eyes Merger with American Airlines in Potential Industry-Shaping Deal 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Anthropic Discusses Frontier AI Model Mythos With Trump Administration Despite Pentagon Ban 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
PHILADELPHIA, June 01, 2017 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that company management will present at or attend several important investment conferences this month.
Specifically, company management will present at:
- Jefferies 2017 Healthcare Conference on Tuesday, June 6, at 4:00 p.m EDT, at the Grand Hyatt in New York
- Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, at 4:00 p.m. PDT, at the Terranea Resort in Rancho Palos Verdes, Calif.
Company management will also participate in the J.P. Morgan European Healthcare Conference on Thursday, June 22, in London.
About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of biallelic RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001 in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 (which also has received both breakthrough therapy and orphan product designations by the FDA, and access to the PRIority MEdicines (PRIME) Program by the EMA) in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer, and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com.
Investor Contact: Ryan Asay [email protected] (215) 239-6424 Media Contact: Monique da Silva [email protected] (215) 282-7470
